Pharmacologic strategies for discontinuing benzodiazepine treatment

Journal of Clinical Psychopharmacology

Volumn 19, Issue 6 SUPPL. 2, 1999, Pages

  Rickels, Karl ^a   DeMartinis, Nicholas ^a   Rynn, Moira ^a   Mandos, Laura ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; IMIPRAMINE; TRAZODONE; VALPROIC ACID;

ANXIETY NEUROSIS; CONFERENCE PAPER; DRUG DEPENDENCE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; TREATMENT INDICATION;

ANTI-ANXIETY AGENTS; ANXIETY; BENZODIAZEPINES; CHEMOTHERAPY, ADJUVANT; DEPRESSION; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032750613     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199912002-00003     Document Type: Conference Paper

References (30)

1. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405.
2. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13[suppl 1]:1S-169S.
3. American Psychiatric Association. Benzodiazepine dependence, toxicity, and abuse. Washington, DC: APA Press, 1990.
4. Petursson H, Lader MH. Withdrawal from long-term treatment. Br Med J (Clin Res Ed) 1981;283:643-5.
5. Winokur A, Rickels K, Greenblatt DJ, Snyder PJ, Schatz NJ. Withdrawal reaction from long-term low dosage administration of diazepam. Arch Gen Psychiatry 1980;37:101-5.
6. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444-50.
7. Schweizer E, Rickels K. Buspirone and related 5-HT compounds as anxiolytics. In: Nutt DJ, Mendelson WB, eds. Hypnotics and anxiolytics. London: Bailliere Tindall, 1995:447-66.
8. Fulton B, Brogden B. Buspirone. An updated review of its clinical pharmacology and therapeutic pharmacology and therapeutic applications. Adis Drug Evaluation. CNS Drugs 1997;1:68-88.
9. Rickels K, Schweizer E. The clinical presentation of generalized anxiety in primary care settings: practical concepts of classification and management. J Clin Psychiatry 1997;58[suppl 11]:4-10.
10. Rickels K, Case WG, Schweizer E, Garcia-España F, Fridman R. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991;148:757-61.
11. Ciraulo DA, Barnhill JG, Ciraulo AM, Greenblatt DJ, Shader RI. Parental alcoholism as a risk factor in benzodiazepine use: a pilot study. Am J Psychiatry 1989;146:1333-5.
12. Ciraulo DA, Sarid-Segal O, Knapp C, Ciraulo AM, Greenblatt DJ, Shader RI. Liability to alprazolam abuse in daughters of alcoholics. Am J Psychiatry 1996;153:956-8.
13. Lucki I, Volpicelli JR, Schweizer E. Differential craving between recovering abstinent alcoholic-dependent subjects and therapeutic users of benzodiazepines. NIDA Res Monogr 1991;105:322-3.
14. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907.
15. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic uses of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990;47:908-15.
16. Rickels K, Schweizer E, Case WG, Garcia-España F. Benzodiazepine dependence, withdrawal severity, and clinical outcome: effects of personality. Psychopharmacol Bull 1988;24:415-20.
17. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-90.
18. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A. Does cognitive behavior therapy slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994;151:876-81.
19. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance of drug treatment for panic disorder. II. Short-and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-8.
20. Schweizer E, Rickels K, DeMartinis N, Case G, Garcia-España F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine patients. Psychol Med 1998;28:713-20.
21. Rickels K, Case WG, Schweizer E, Garcia-Espana F, Fridman R. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991;148:757-61.
22. Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981;1:520-2.
23. Schweizer E, Case WG, Garcia-España F, Greenblatt DJ, Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology (Berl) 1995;117:424-9.
24. 3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol 1998;18:121-31.
25. Tyrer P, Ferguson B, Hallstrom C, Michie M, Tyrer S, Cooper S, Caplan R, Barczak P. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry 1996;168:457-61.
26. Schweizer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986;143:1590-2.
27. Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 1987;7:11-5.
28. Chiaie RP, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 1995;15:12-9.
29. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and taper outcome. Arch Gen Psychiatry 1991;48:448-52.
30. Rickels K, Schweizer E, Garcia-España F, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects of withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999;141:1-5.